Solésence to Join Russell 3000® and Russell 2000® Indexes
Rhea-AI Summary
Solésence (Nasdaq: SLSN), a healthcare solutions provider specializing in beauty and life science, has announced its upcoming inclusion in both the Russell 3000® and Russell 2000® Indexes, effective June 30, 2025. This milestone follows the company's recent Nasdaq uplisting and is part of the 2025 Russell indexes reconstitution.
The inclusion is based on FTSE Russell's objective market-capitalization rankings, which capture the 4,000 largest US stocks as of April 30. This development is particularly significant as approximately $10.6 trillion in assets are benchmarked against Russell US indexes, potentially increasing Solésence's visibility among institutional investors.
Positive
- Inclusion in Russell 3000® and Russell 2000® Indexes increases institutional investor visibility
- Recent uplisting to Nasdaq demonstrates company growth trajectory
- Access to $10.6 trillion in benchmarked assets could improve trading liquidity
- Automatic inclusion in appropriate growth and value style indexes
Negative
- None.
Insights
Solésence's Russell index inclusion increases institutional visibility and potential liquidity, following their Nasdaq uplisting—a positive market structure development.
Solésence's forthcoming addition to the Russell 3000® and Russell 2000® Indexes represents a significant milestone in the company's capital markets evolution. This development, effective June 30, 2025, follows their recent Nasdaq uplisting and creates a structural enhancement to their market presence.
Index inclusion brings several tangible benefits: passive funds tracking these benchmarks must purchase shares, typically enhancing trading volume and liquidity. With approximately
Being specifically included in the Russell 2000® positions Solésence in the small-capitalization segment of the market, providing important context on their current market position. Their dual inclusion in both the broad-market Russell 3000® and small-cap Russell 2000® also means automatic categorization in appropriate growth and value style indexes, potentially attracting different investor types.
This market structure improvement aligns with management's strategic vision, as CEO Jess Jankowski emphasized leveraging this milestone to sustain growth momentum in their health care solutions business across beauty and life science categories. While index inclusion doesn't directly impact operational fundamentals, it removes a technical barrier for institutional investment and generally improves a company's capital markets profile.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.
The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“Joining both the Russell 3000® and Russell 2000® Indexes is a major achievement for our entire organization,” said Jess Jankowski, President and Chief Executive Officer of Solésence. “This milestone, following our recent uplisting to Nasdaq, significantly enhances our exposure to a wider range of institutional investors. As we continue to invest in developing industry-leading, award-winning skin health solutions, we look forward to leveraging this milestone to help sustain our growth momentum in the years to come.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about
For more information on the Russell 3000® Index, the Russell 2000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About Solésence, Inc.
Solésence, Inc. (Nasdaq: SLSN), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
Forward-Looking Statements
This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2025. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
Media Contact:
media@solesence.com
Investor Relations Contact:
investors@solesence.com
